Crossmark

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer

Crossref DOI link: https://doi.org/10.1186/s12885-018-4925-1

Published Online: 2018-10-29

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gass, Paul http://orcid.org/0000-0002-4239-5528
Lux, Michael P.

Rauh, Claudia

Hein, Alexander

Bani, Mayada R.

Fiessler, Cornelia

Hartmann, Arndt

Häberle, Lothar

Pretscher, Jutta

Erber, Ramona

Wachter, David L.

Schulz-Wendtland, Rüdiger

Beckmann, Matthias W.

Fasching, Peter A.

Wunderle, Marius
License Information

Text and Data Mining valid from 2018-10-29
More Information

Article History

Received: 18 June 2017

Accepted: 9 October 2018

First Online: 29 October 2018

Ethics approval and consent to participate

: This retrospective study and the anonymized scientific use of the data were approved by the ethics committee of the medical faculty of the University of Erlangen–Nuremberg. Informed consent was obtained from each individual participant included in the study.

: Not applicable.

: PG has received honoraria from Novartis and financial support for symposia from Novartis, Roche, and PharmaMar. MPL has received honoraria from MSD and AstraZeneca. A Hartmann is member of the Editorial Board of BMC Cancer as Associate Editor. PAF has received honoraria from Roche, Amgen, Celgene, Novartis, and Pfizer. The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.